Diaceutics PLC PDMR Shareholding/Share Incentive Plan (5455D)
29 Junio 2021 - 10:56AM
UK Regulatory
TIDMDXRX
RNS Number : 5455D
Diaceutics PLC
29 June 2021
29 June 2021
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation
company for precision testing has been notified that on 28 June
2021 Zedra Trust Company (Guernsey) Limited, the trustees of the
Global Diaceutics plc 2020 Employee Benefit Trust ("EBT"), have
purchased ordinary shares ("Shares") on behalf of Susanne Munksted
and Damian Thornton (both PDMRs), in respect of their purchase of
Shares pursuant to the Company's Global Share Incentive Plan
("Global SIP Scheme") for international employees. These purchases
will be made each month until further notice.
As announced on 30 April 2021, under the SIP Scheme, the Company
will match this purchase with a matched share award being the grant
of a single one-off option over an equivalent number of Shares
purchased by the employee, over the forthcoming period to April
2022 and subsequent 12 month periods thereafter, in the proportion
of 2:1 for all purchases up to and including April 2022 and 1:1 for
all purchases thereafter. The options will be formally granted in
the future, expected to be within July, at an exercise price of
nil.
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ -----------------------------------------------------------------------------------------------
a. Name Susanne Munksted
---------------------------------------------------
2 Reason for notification
------------------------------------------ ---------------------------------------------------
a. Position/Status Managing Director and PDMR
------------------------------------------ ---------------------------------------------------
b. Initial notification/ Initial
Amendment
---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ -----------------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ---------------------------------------------------
b. Nature of the Ongoing non-discretionary purchase of Shares
transaction to be matched by the future grant of nil
cost options over Shares under the Global
Share Incentive Plan ("SIP")
------------------------------------------ ---------------------------------------------------
c. Price(s) and volume(s) Share purchase:
------------------------------------------ -----------------------------------------------
Price(s) Volume(s)
------------------------------------------ -----------------------
130.00 p 111
----------------------- ----------------------
Matching option award:
Option over 222 Shares (exercise price:
nil) to be awarded in July 2021
-----------------------------------------------------------------------------------------------------
e. Date of the transaction Share purchase: 28 June 2021
Option award: To be formally entered into
in July 2021
------------------------------------------ ---------------------------------------------------
f. Place of the transaction Share Purchase: AIM Market of the London
Stock Exchange
Future option award: Off-Market
------------------------------------------ ---------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ -----------------------------------------------------------------------------------------------
a. Name Damian Thornton
---------------------------------------------------
2 Reason for notification
------------------------------------------ ---------------------------------------------------
a. Position/Status Chief Operating Officer and PDMR
------------------------------------------ ---------------------------------------------------
b. Initial notification/ Initial
Amendment
---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
------------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ -----------------------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
------------------------------------------ ---------------------------------------------------
b. Nature of the Ongoing non-discretionary purchase of Shares
transaction to be matched by the future grant of nil
cost options over Shares under the Global
Share Incentive Plan ("SIP")
------------------------------------------ ---------------------------------------------------
c. Price(s) and volume(s) Share purchase:
------------------------------------------ -----------------------------------------------
Price(s) Volume(s)
------------------------------------------ -----------------------
130.00 p 114
----------------------- ----------------------
Matching option award:
Option over 228 Shares (exercise price:
nil) to be awarded in July 2021
-----------------------------------------------------------------------------------------------------
e. Date of the transaction Share purchase: 28 June 2021
Option award: To be formally entered into
in July 2021
------------------------------------------ ---------------------------------------------------
f. Place of the transaction Share Purchase: AIM Market of the London
Stock Exchange
Future option award: Off-Market
------------------------------------------ ---------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKCBPPBKDNAB
(END) Dow Jones Newswires
June 29, 2021 11:56 ET (15:56 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
